... acute lymphoid leukemia (ALL), chronic lymphocytic leukemia (CLL) and chronic myelogenous leukemia (CML ... Although mouse models have been successful for studying leukemia stem cells in MLL-associated AML ...
... mathematical model that may lead to the development of an optimally-timed vaccine for chronic myelogenous leukemia (CML). The model takes into account the natural anti-leukemia response in patients ...
... study that combined math and medicine, researchers have shown that patients with chronic myelogenous leukemia may be cured of the disease with an optimally timed cancer vaccine, where the timing is ...
... identified that a combination of novel anti-cancer compounds is able to kill chronic myelogenous leukemia cells previously resistant to conventional forms of therapy. Chronic myelogenous leukemia, or ...
... both genetic and epigenetic mechanisms in several mouse and human blood cell malignancies, including chronic myelogenous leukemias and some acute lymphoblastic leukemias.
The researchers went on to ...
Activation of LYN kinase is associated with resistance to imatinib (Gleevec) in patients with chronic myelogenous leukemia (CML), researchers report in the June 24 online issue of the Journal of the ...
... of each patient's tumor, a strategy that has been effective in multiple cancer types, including breast cancer, lung cancer and chronic myelogenous leukemia.
... as Gleevec. The drug, known to inhibit c-kit, currently is used to treat chronic myelogenous leukemia and other cancers.
Positron emission tomography scans showed that Gleevec halved the metabolic ...
... activity and size of the tumors.
Because Gleevec is already prescribed for chronic myelogenous leukemia and other cancers, the researchers were able to secure fast regulatory approval for a phase 2 ...
... whose research helped identify the targeted drug Gleevec as a promising therapy for chronic myelogenous leukemia. Druker, the director of the Oregon Health & Science University Cancer Institute and a ...
... at this point," de Lima said.
Patients with recurrent, high-risk acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, many types of lymphoma, aplastic anemia ...
Two drugs approved as fallback therapy for chronic myelogenous leukemia (CML) appear to outperform historical benchmarks of the frontline medication when used as a first treatment in separate clinical ...
... is more than just wishful thinking: Patients suffering from a type of blood cancer called chronic myelogenous leukemia who are treated with a drug called Gleevec almost always relapse ...
... in mouse models with drug-resistant chronic myelogenous leukemia (CML) are the subject of an advance online ... , M.D., Chairman and Professor, Department of Leukemia, at M.D. Anderson Cancer Center in ...
... inhibit a single protein to stop intrinsic enzymatic activity; one example is Gleevec, used for chronic myelogenous leukemia (CML). The Ewing's sarcoma fusion protein, known as EWS-FLI1, lacks ...
